Literature DB >> 3871646

Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds.

M V Ragni, D Sinha, F Seaman, J H Lewis, J A Spero, P N Walsh.   

Abstract

The relationship of clinical bleeding tendency and factor XI antigen (XI:Ag) in factor XI deficiency was studied in 78 members of 25 factor XI-deficient kindreds. Factor XI:Ag was measured in a competitive radioimmunoassay, using monospecific, heterologous anti-factor XI antibody. 125I-labeled factor XI, and staphylococcal protein A as the precipitating agent. Deficiency of factor XI clotting activity (XI:C), less than 0.62 U/mL, occurred in 48 individuals, 22 of whom experienced postoperative or posttraumatic bleeding: Their mean factor XI:C was 0.21 +/- 0.04 U/mL (SEM), and factor XI:Ag was 0.23 +/- 0.04 U/mL. The remaining 26 had no clinical bleeding, many despite surgical challenge: Their mean factor XI:C was 0.30 +/- 0.04 U/mL, and factor XI:Ag was 0.34 +/- 0.05 U/mL. In all, 13 kindreds had between 1 and 11 members with bleeding; the other 12 had none with deficient hemostasis. Two heterozygous factor XI-deficient individuals appeared to be positive for cross-reacting material (CRM+). The slope of the regression line for factor XI:C and factor XI:Ag data points in the 78 individuals tested did not differ from control, and all points fell within 95% confidence limits derived from control. In conclusion, bleeding tendency appears to be consistent within a given kindred and is not determined exclusively by factor XI:C or factor XI:Ag levels.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871646

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations.

Authors:  R Asakai; D W Chung; O D Ratnoff; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.

Authors:  Feng Xu; Judianne Davis; Jianting Miao; Mary Lou Previti; Galina Romanov; Kelly Ziegler; William E Van Nostrand
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

3.  Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.

Authors:  M C Minnema; P W Friederich; M Levi; P A von dem Borne; L O Mosnier; J C Meijers; B J Biemond; C E Hack; B N Bouma; H ten Cate
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

4.  Mechanism of activation of coagulation factor XI by factor XIIa studied with monoclonal antibodies.

Authors:  H Akiyama; D Sinha; F S Seaman; E P Kirby; P N Walsh
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

5.  Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.

Authors:  Likui Yang; Mao-fu Sun; David Gailani; Alireza R Rezaie
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

6.  Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency.

Authors:  M Zucker; U Seligsohn; O Salomon; A S Wolberg
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

Review 7.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

8.  Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.

Authors:  Georgios Mavromatidis; Konstantinos Dinas; Dimitrios Delkos; Fotios Goutzioulis; Christos Vosnakis; Emmanouel Hatzipantelis; Vassilia Garipidou; David Rousso
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

9.  A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets.

Authors:  Tara N Miller; Dipali Sinha; T Regan Baird; Peter N Walsh
Journal:  Biochemistry       Date:  2007-11-17       Impact factor: 3.162

10.  Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency.

Authors:  Gillian N Gidley; Lori A Holle; John Burthem; Paula H B Bolton-Maggs; Feng-Chang Lin; Alisa S Wolberg
Journal:  Blood Adv       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.